



G1 Therapeutics to Host Investor Day 2019 on March 6, 2019

February 27, 2019

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2019 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host its Investor Day 2019 on Wednesday, March 6 in New York City, beginning at 8:00 a.m. ET and concluding at approximately 10:30 a.m. ET.

The G1 management team will provide a comprehensive overview of the company's three clinical development programs and outline the commercialization strategy for its lead product candidate, trilaciclib. Jeffrey Crawford, M.D., Co-director, Solid Tumor Therapeutics Program, Duke Cancer Institute, will review the consequences of chemotherapy-related myelosuppression. Lowell Hart, M.D., Scientific Director of Research, Florida Cancer Specialists and trilaciclib clinical trial investigator, will discuss his clinical experience in treating cancer patients and the potential role of trilaciclib in the oncology treatment paradigm.

The event will be webcast live and accessible on the [Events & Presentations](#) page on the company's website: www.g1therapeutics.com. The webcast will be archived on the same page following the event.

About G1 Therapeutics

[G1 Therapeutics, Inc.](#) is a clinical-stage biopharmaceutical company focused on the discovery, development and delivery of innovative therapies that improve the lives of those affected by cancer. The company is advancing three clinical-stage programs, [trilaciclib](#), [lerociclib](#) and [G1T48](#), that are designed to enable more effective combination treatment strategies and improve patient outcomes across multiple oncology indications. G1 also has an active discovery program focused on cyclin-dependent kinases targets.

G1 is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contact:

Jeff Macdonald
Head of Investor Relations/Public Relations
919-907-1944
jmacdonald@g1therapeutics.com



Source: G1 Therapeutics